Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
NCT07085273
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
Irinotecan Liposomal
Sponsor
The First Affiliated Hospital of Zhengzhou University